GALT (Galectin Therapeutics) LT-Debt-to-Total-Asset: 8.61 (As of Mar. 2026)


GALT Galectin Therapeutics Inc GALT
16 GF Score
Price $4.64
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics LT-Debt-to-Total-Asset?

Galectin Therapeutics GALT -6.64% 16 LT-Debt-to-Total-Asset is 8.61 as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 16/100. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Galectin Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 8.61.

Galectin Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (1.14) to Mar. 2026 (8.61). It may suggest that Galectin Therapeutics is progressively becoming more dependent on debt to grow their business.

Galectin Therapeutics  (NAS:GALT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Galectin Therapeutics LT-Debt-to-Total-Asset Related Terms

Galectin Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics LT-Debt-to-Total-Asset Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 1.87 2.54 4.87 6.85

Galectin Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 7.72 0.00 6.85 8.61
GALT
16GF Score
Galectin Therapeutics Inc GALT
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics LT-Debt-to-Total-Asset Calculation

Galectin Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=133.735/19.532
=

Galectin Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=135.71/15.759
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 8.61 mean?
Galectin Therapeutics (GALT) has a LT-Debt-to-Total-Asset of 8.61 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Galectin Therapeutics and its competitors.
Is Galectin Therapeutics' LT-Debt-to-Total-Asset too high?
Galectin Therapeutics' current LT-Debt-to-Total-Asset is 8.61. Overall, Galectin Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' LT-Debt-to-Total-Asset compare to PALI and IRD?
Galectin Therapeutics' LT-Debt-to-Total-Asset of 8.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Galectin Therapeutics and its competitors. Galectin Therapeutics's current LT-Debt-to-Total-Asset is 8.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current LT-Debt-to-Total-Asset of 8.61. The current LT-Debt-to-Total-Asset is 8.61. Galectin Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current LT-Debt-to-Total-Asset is 8.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
16GF Score

Get the complete analysis for GALT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.64
Price